Promising combo for rare blood cancer shows early potential

NCT ID NCT05051891

Completed Disease control Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial tested whether adding the targeted drug orelabrutinib to standard chemotherapy (R-CHOP) works better than chemotherapy alone for people with untreated mantle cell lymphoma, a rare blood cancer. Only 3 patients took part, and the study is now complete. Researchers measured how long patients lived without the cancer getting worse, overall response, and survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Orelabrutinib combined with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)
What this could lead to: If successful, this combination could offer a more effective first treatment for mantle cell lymphoma, potentially delaying disease progression.
What could go wrong: This was a very small completed trial with only 3 participants, so results may not apply broadly. The combination also carries risks from chemotherapy and targeted therapy side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mantle cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TREATMENT-NAЇVE MANTLE CELL LYMPHOMA

Contacts and locations

Locations

Anhui Province Cancer Hospital

Hefei, Anhui, 230009, China
Beijing Cancer Hospital

Beijing, Beijing Municipality, 100143, China
Guangzhou First People's Hospital

Guangzhou, Guangdong, 510180, China
Henan Tumor Hospital

Zhengzhou, Henan, 450008, China
Hospital of Hematology, Chinese Academy of Medical Sciences

Tianjin, Tianjin Municipality, 300052, China
Jiangsu Province Hospital

Nanjing, Jiangsu, 210029, China
Shandong Provincial Hospital

Jinan, Shandong, 250021, China
Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, 510060, China
The First Affiliated Hospital of Guangxi Medical University

Guangxi, Nanning, 530021, China
The First Affiliated Hospital of Nanchang University

Nanchang, Jiangxi, 3300008, China
The First Affiliated Hospital of Soochow University

Suzhou, Jiangsu, 215006, China
The First Affiliated Hospital of Xiamen University

Xiamen, Fujian, 361003, China
The First Affiliated Hospital of Zhengzhou University

Zhengzhou, Henan, 450052, China
The First Hospital of China Medical University

Shenyang, Liaojing, 110001, China
The First Hospital of Jilin University

Changchun, Jilin, 130021, China
The Fourth Hospital of Hebei Medical University

Shijiazhuang, Hebei, 50011, China
Tianjin Cancer Hospital

Tianjin, Tianjin Municipality, 300060, China
Tumor in Hunan Province

Hunan, Changsha, 410013, China
West China Hospital,Sichuan University

Chengdu, Sichuan, 610041, China
Wuhan Union Hospital

Wuhan, Hubei, 430022, China
Zhejiang Cancer Hospital

Hangzhou, Zhejiang, 310022, China
he First Affiliated Hospital of Zhengjiang University

Hangzhou, Zhejiang, 310003, China